» Articles » PMID: 35636503

Substrate-selective Positive Allosteric Modulation of PTPRD's Phosphatase by Flavonols

Overview
Date 2022 May 31
PMID 35636503
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor type protein tyrosine phosphatase D (PTPRD) is expressed by neurons and implicated in interesting phenotypes that include reward from addictive substances, restless leg syndrome and neurofibrillary tangle densities in Alzheimer's disease (AD-NFTs). However, the brain phosphotyrosine phosphoprotein (PTPP) substrates for PTPRD's phosphatase have not been clearly defined. Although we have identified small molecule inhibitors of PTPRD's phosphatase that are candidates for reducing reward from addictive substances, no positive allosteric modulators of this phosphatase that might be candidates for reducing AD-NFTs have been reported. We now report identification of candidate brain substrates for PTPRD based on their increased phosphorylation in knockout vs wildtype animals, coexpression with PTPRD in neuronal subtypes and brisk dephosphorylation by recombinant human PTPRD phosphatase. We also report discovery that quercetin and other flavonols, though not closely-related flavones, enhance rates of PTPRD's dephosphorylation of a group of these candidate substrate PTPPs but not others. This substrate-selective positive allosteric modulation provides a novel pharmacological action. Flavonol-mediated increases in PTPRD's dephosphorylation of the GSK3 β and α kinases that hyperphosphorylate tau, the major component of AD-NFTs, could help to explain recent data concerning genetic and dietary impacts on Alzheimer's disease.

Citing Articles

Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D.

Uhl G Front Psychiatry. 2023; 14:1031283.

PMID: 37139308 PMC: 10149857. DOI: 10.3389/fpsyt.2023.1031283.

References
1.
Nakagawa T, Itoh M, Ohta K, Hayashi Y, Hayakawa M, Yamada Y . Improvement of memory recall by quercetin in rodent contextual fear conditioning and human early-stage Alzheimer's disease patients. Neuroreport. 2016; 27(9):671-6. DOI: 10.1097/WNR.0000000000000594. View

2.
Drgonova J, Walther D, Wang K, Hartstein G, Lochte B, Troncoso J . Mouse Model for Protein Tyrosine Phosphatase D () Associations with Restless Leg Syndrome or Willis-Ekbom Disease and Addiction: Reduced Expression Alters Locomotion, Sleep Behaviors and Cocaine-Conditioned Place Preference. Mol Med. 2015; 21(1):717-725. PMC: 4749486. DOI: 10.2119/molmed.2015.00017. View

3.
Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W . Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27(3):221-34. DOI: 10.1007/s10822-013-9644-8. View

4.
Cancino G, Perez de Arce K, Castro P, Toledo E, von Bernhardi R, Alvarez A . c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice. Neurobiol Aging. 2009; 32(7):1249-61. DOI: 10.1016/j.neurobiolaging.2009.07.007. View

5.
Shishikura M, Nakamura F, Yamashita N, Uetani N, Iwakura Y, Goshima Y . Expression of receptor protein tyrosine phosphatase δ, PTPδ, in mouse central nervous system. Brain Res. 2016; 1642:244-254. DOI: 10.1016/j.brainres.2016.03.030. View